@article{5a33726b42994b41ac29b88ca53a82b4,
title = "Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis",
abstract = "Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes. Here we describe a genome-wide CRISPR/Cas9-mediated loss-of-function screen in tumor growth and metastasis. We mutagenized a non-metastatic mouse cancer cell line using a genome-scale library with 67,405 single-guide RNAs (sgRNAs). The mutant cell pool rapidly generates metastases when transplanted into immunocompromised mice. Enriched sgRNAs in lung metastases and late-stage primary tumors were found to target a small set of genes, suggesting that specific loss-of-function mutations drive tumor growth and metastasis. Individual sgRNAs and a small pool of 624 sgRNAs targeting the top-scoring genes from the primary screen dramatically accelerate metastasis. In all of these experiments, the effect of mutations on primary tumor growth positively correlates with the development of metastases. Our study demonstrates Cas9-based screening as a robust method to systematically assay gene phenotypes in cancer evolution in vivo.",
author = "Sidi Chen and Sanjana, {Neville E.} and Kaijie Zheng and Ophir Shalem and Kyungheon Lee and Xi Shi and Scott, {David A.} and Jun Song and Pan, {Jen Q.} and Ralph Weissleder and Hakho Lee and Feng Zhang and Sharp, {Phillip A.}",
note = "Funding Information: We thank R. Weinberg and R. Kerbel for critically reading the manuscript; the entire P.A.S. lab and F.Z. lab, L. Cong, T. Kelly, X. Ni, M. Nobel, J. Boehm, A. Tsherniak, S. Levine, M. Cornwall-Brady, S. Malstrom, M. Jennings, E. Vasile, C. Whittaker, K. Cormier, R. Bronson, and colleagues at the Koch Institute, Broad Institute, McGovern Institute, and Department of Biology for technical assistance and/or discussion; the Swanson Biotechnology Center for technical support (Genomics, Animal Imaging and Preclinical Testing, Bioinformatics and Computing, Microscopy, Flow Cytometry, Microscopy, and Histology, in particular). This work is supported by grants to P.A.S., including a United States Public Health Service grant R01-CA133404 from the NIH, an MIT-Harvard Center for Cancer Nanotechnology Excellence Grant U54 CA151884 from the National Cancer Institute, a generous gift from the Marie D. and Pierre Casimir-Lambert Fund, an SkTech/MIT Initiative Grant from the Skolkovo Foundation, and the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute. F.Z. is supported by the NIH through NIMH grant 5DP1-MH100706) and NIDDK grant 5R01-DK097768; a Waterman Award from the National Science Foundation; the Keck, New York Stem Cell, Damon Runyon, Searle Scholars, Merkin, and Vallee foundations; and Bob Metcalfe. F.Z. is a New York Stem Cell Foundation Robertson Investigator. S.C. is a Damon Runyon Cancer Research Fellow (DRG-2117-12) and also supported by the Dale Frey Award for Breakthrough Scientists. N.E.S. is supported by a Simons Center for the Social Brain Postdoctoral Fellowship and NIH NHGRI award K99-HG008171. O.S. is a fellow of the Klarman Cell Observatory. R.W. is supported by NIH grant U54 CA151884. D.A.S. is supported by a NSF Graduate Research Fellowship. H.L. is supported by Department of Defense grant OCRP W81XWH-14-1-0279. CRISPR reagents (plasmids and libraries) are available to the academic community through Addgene. F.Z. is a co-founder of Editas Medicine and a scientific advisor for Editas Medicine and Horizon Discovery. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = mar,
day = "15",
doi = "10.1016/j.cell.2015.02.038",
language = "English (US)",
volume = "160",
pages = "1246--1260",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "6",
}